Drug Type Small molecule drug |
Synonyms AMP-886, CTX-294886 |
Target |
Action inhibitors, antagonists |
Mechanism FAK inhibitors(Focal adhesion kinase inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), VEGFR3 antagonists(Vascular endothelial growth factor receptor 3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hematologic Neoplasms | Preclinical | - | 07 Feb 2024 | |
| Solid tumor | Preclinical | - | 07 Feb 2024 | |
| Pulmonary Fibrosis | Preclinical | - | - | |
| Pulmonary Fibrosis | Preclinical | - | - | |
| Pulmonary Fibrosis | Preclinical | - | - |





